1. Gastroesophageal Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023.
- Author
-
Scheck, Magdalena K., Ekmekciu, Ira, Sommerhäuser, Greta, Heise, Christian, Mavroeidi, Ilektra Antonia, Kunzmann, Volker, Wege, Henning, Reinacher-Schick, Anke, Hofheinz, Ralf-Dieter, Oliver Götze, Thorsten, Lorenzen, Sylvie, and Nieto, Alexander Edward
- Subjects
MEDICAL societies ,ESOPHAGEAL cancer ,ONCOLOGY ,CLINICAL trials ,ANNUAL meetings ,ESOPHAGOGASTRIC junction cancer - Abstract
The European Society for Medical Oncology (ESMO) annual meeting in Madrid in October 2023 showcased advancements in gastroesophageal oncology. Several studies were presented, including the SANO trial, which found that active surveillance after neoadjuvant chemoradiotherapy could be an alternative to standard resection for patients with locally advanced esophageal cancer. The Keynote-585 study explored the addition of pembrolizumab to perioperative chemotherapy for gastroesophageal adenocarcinoma and found improved response rates and event-free survival. The Matterhorn study showed that adding durvalumab to perioperative chemotherapy increased response rates in gastroesophageal cancer. Additionally, the Keynote-811 trial demonstrated that pembrolizumab improved progression-free survival in HER2-positive advanced gastroesophageal adenocarcinoma. The text also discussed trials evaluating treatments for HER2-negative metastatic gastric or gastroesophageal junction cancer, including pembrolizumab, sugemalimab, and zolbetuximab, which all showed promising results in improving survival and response rates. These findings provide potential treatment options for patients with HER2-negative mGC/GEJC. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF